Search Results

There are 45553 results for: content related to: Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I

  1. New insights into small-molecule inhibitors of Bcr-Abl

    Medicinal Research Reviews

    Volume 31, Issue 1, January 2011, Pages: 1–41, S. Schenone, O. Bruno, M. Radi and M. Botta

    Version of Record online : 27 AUG 2009, DOI: 10.1002/med.20175

  2. Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance

    Chemical Biology & Drug Design

    Volume 77, Issue 1, January 2011, Pages: 1–11, Tianjun Zhou, Lois Commodore, Wei-Sheng Huang, Yihan Wang, Mathew Thomas, Jeff Keats, Qihong Xu, Victor M. Rivera, William C. Shakespeare, Tim Clackson, David C. Dalgarno and Xiaotian Zhu

    Version of Record online : 30 NOV 2010, DOI: 10.1111/j.1747-0285.2010.01054.x

  3. You have full text access to this OnlineOpen article
    Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation

    Cancer

    Volume 123, Issue 15, August 01, 2017, Pages: 2875–2880, Franck E. Nicolini, Grzegorz W. Basak, Dong-Wook Kim, Eduardo Olavarria, Javier Pinilla-Ibarz, Jane F. Apperley, Timothy Hughes, Dietger Niederwieser, Michael J. Mauro, Charles Chuah, Andreas Hochhaus, Giovanni Martinelli, Maral DerSarkissian, Mei Sheng Duh, Lisa J. McGarry, Hagop M. Kantarjian and Jorge E. Cortes

    Version of Record online : 7 APR 2017, DOI: 10.1002/cncr.30558

  4. Crystal Structure of the T315I Mutant of Abl Kinase

    Chemical Biology & Drug Design

    Volume 70, Issue 3, September 2007, Pages: 171–181, Tianjun Zhou, Lois Parillon, Feng Li, Yihan Wang, Jeff Keats, Sarah Lamore, Qihong Xu, William Shakespeare, David Dalgarno and Xiaotian Zhu

    Version of Record online : 20 AUG 2007, DOI: 10.1111/j.1747-0285.2007.00556.x

  5. You have full text access to this Open Access content
    Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: In vitro and in vivo studies

    Cancer Science

    Volume 99, Issue 6, June 2008, Pages: 1251–1257, Daigo Akahane, Tetsuzo Tauchi, Seiichi Okabe, Kousuke Nunoda and Kazuma Ohyashiki

    Version of Record online : 21 APR 2008, DOI: 10.1111/j.1349-7006.2008.00810.x

  6. You have free access to this content
    Site-specific cleavage of mutant ABL mRNA by DNAzyme is facilitated by peptide nucleic acid binding to RNA substrate

    FEBS Letters

    Volume 586, Issue 21, November 02, 2012, Pages: 3865–3869, Ji Eun Kim, Soojin Yoon, Hyejung Mok, Woong Jung and Dong-Eun Kim

    Version of Record online : 23 SEP 2012, DOI: 10.1016/j.febslet.2012.09.013

  7. You have free access to this content
    Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring

    American Journal of Hematology

    Volume 91, Issue 2, February 2016, Pages: 252–265, Elias Jabbour and Hagop Kantarjian

    Version of Record online : 22 JAN 2016, DOI: 10.1002/ajh.24275

  8. You have free access to this content
    The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm

    Cancer

    Volume 118, Issue 2, 15 January 2012, Pages: 293–299, Don L. Gibbons, Sabrina Pricl, Hagop Kantarjian, Jorge Cortes and Alfonso Quintás-Cardama

    Version of Record online : 5 JUL 2011, DOI: 10.1002/cncr.26225

  9. C6-Unsubstituted Pyrazolo[3,4-d]pyrimidines Are Dual Src/Abl Inhibitors Effective against Imatinib Mesylate Resistant Chronic Myeloid Leukemia Cell Lines

    ChemMedChem

    Volume 4, Issue 1, January 12, 2009, Pages: 118–126, Maria Alessandra Santucci, Valentina Corradi, Manuela Mancini, Fabrizio Manetti, Marco Radi, Silvia Schenone and Maurizio Botta

    Version of Record online : 27 NOV 2008, DOI: 10.1002/cmdc.200800320

  10. You have full text access to this OnlineOpen article
    Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells

    Cancer Science

    Volume 107, Issue 7, July 2016, Pages: 1029–1038, Yasufumi Matsuda, Takahiro Yamauchi, Naoko Hosono, Kanako Uzui, Eiju Negoro, Koji Morinaga, Rie Nishi, Akira Yoshida, Shinya Kimura, Taira Maekawa and Takanori Ueda

    Version of Record online : 21 JUN 2016, DOI: 10.1111/cas.12965

  11. You have free access to this content
    Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

    Cancer

    Volume 117, Issue 9, 1 May 2011, Pages: 1800–1811, Elias Jabbour, Susan Branford, Giuseppe Saglio, Dan Jones, Jorge E. Cortes and Hagop M. Kantarjian

    Version of Record online : 29 NOV 2010, DOI: 10.1002/cncr.25717

    Corrected by:

    Erratum: Erratum

    Vol. 117, Issue 15, 3535, Version of Record online: 10 JAN 2011

  12. You have full text access to this OnlineOpen article
    A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia

    EMBO Molecular Medicine

    Volume 5, Issue 3, March 2013, Pages: 353–365, Jiewen Zhu, Longen Zhou, Guikai Wu, Heiko Konig, Xiaoqin Lin, Guideng Li, Xiao-Long Qiu, Chi-Fen Chen, Chun-Mei Hu, Erin Goldblatt, Ravi Bhatia, A. Richard Chamberlin, Phang-Lang Chen and Wen-Hwa Lee

    Version of Record online : 22 JAN 2013, DOI: 10.1002/emmm.201201760

  13. You have free access to this content
    Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation

    British Journal of Haematology

    Volume 157, Issue 3, May 2012, Pages: 407–410, Marie-Magdelaine Coude, Odile Luycx, Marie-Estelle Cariou, Odile Maarek, Hervé Dombret, Jean-Michel Cayuela and Delphine Rea

    Version of Record online : 9 JAN 2012, DOI: 10.1111/j.1365-2141.2011.09016.x

  14. You have free access to this content
    Bcr-Abl activates AURKA and AURKB in chronic myeloid leukemia cells via AKT signaling

    International Journal of Cancer

    Volume 134, Issue 5, 1 March 2014, Pages: 1183–1194, Jing Yang, Takayuki Ikezoe, Chie Nishioka, Keiko Udaka and Akihito Yokoyama

    Version of Record online : 3 SEP 2013, DOI: 10.1002/ijc.28434

  15. You have free access to this content
    Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

    Cancer

    Volume 120, Issue 7, 1 April 2014, Pages: 1002–1009, Simona Soverini, Caterina De Benedittis, Cristina Papayannidis, Stefania Paolini, Claudia Venturi, Ilaria Iacobucci, Mario Luppi, Paola Bresciani, Marzia Salvucci, Domenico Russo, Simona Sica, Ester Orlandi, Tamara Intermesoli, Antonella Gozzini, Massimiliano Bonifacio, Gian Matteo Rigolin, Fabrizio Pane, Michele Baccarani, Michele Cavo and Giovanni Martinelli

    Version of Record online : 30 DEC 2013, DOI: 10.1002/cncr.28522

  16. You have free access to this content
    Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL

    International Journal of Cancer

    Volume 122, Issue 12, 15 June 2008, Pages: 2744–2752, Tim Beissert, Alena Hundertmark, Velina Kaburova, Lorena Travaglini, Afsar A. Mian, Clara Nervi and Martin Ruthardt

    Version of Record online : 25 MAR 2008, DOI: 10.1002/ijc.23467

  17. Molecular monitoring and mutation analysis of patients with advanced phase CML and Ph+ ALL receiving dasatinib

    European Journal of Haematology

    Volume 85, Issue 5, November 2010, Pages: 399–404, Ulla Olsson-Strömberg, Monica Hermansson, Tuija Lundán, Anne-Charlotte Ohm, Ida Engdahl, Martin Höglund, Bengt Simonsson, Kimmo Porkka and Gisela Barbany

    Version of Record online : 26 JUL 2010, DOI: 10.1111/j.1600-0609.2010.01506.x

  18. You have free access to this content
    Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009

    Cancer

    Volume 115, Issue 23, 1 December 2009, Pages: 5382–5393, Alfonso Quintás-Cardama, Hagop Kantarjian and Jorge Cortes

    Version of Record online : 8 SEP 2009, DOI: 10.1002/cncr.24601

  19. You have free access to this content
    AP24163 Inhibits the Gatekeeper Mutant of BCR-ABL and Suppresses In vitro Resistance

    Chemical Biology & Drug Design

    Volume 75, Issue 2, February 2010, Pages: 223–227, Mohammad Azam, John T. Powers, William Einhorn, Wei-Sheng Huang, William C. Shakespeare, Xiaotian Zhu, David Dalgarno, Tim Clackson, Tomi K. Sawyer and George Q. Daley

    Version of Record online : 17 DEC 2009, DOI: 10.1111/j.1747-0285.2009.00911.x

  20. You have free access to this content
    Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease

    British Journal of Haematology

    Volume 142, Issue 3, August 2008, Pages: 361–378, Peter Valent

    Version of Record online : 6 JUN 2008, DOI: 10.1111/j.1365-2141.2008.07197.x